Literature DB >> 12202400

Differential regulation of maturation and apoptosis of human monocyte-derived dendritic cells mediated by MHC class II.

Anna E Lokshin1, Pawel Kalinski, R Rita Sassi, Robbie B Mailliard, Jan Müller-Berghaus, Walter J Storkus, Xiaojun Peng, Adele M Marrangoni, Robert P Edwards, Elieser Gorelik.   

Abstract

Antigen-driven interaction of dendritic cells (DC) with CD4(+) T(h) cells results in the exchange of bidirectional activating signals. Cross-linking of TCR by MHC class II-bound antigen activates T(h) cells, resulting in their up-regulation of CD40 ligand. Here we show that MHC class II molecules, in addition to their passive role in DC-T(h) cell interaction, can also actively induce DC maturation. Cross-linking of MHC class II molecules on human monocyte-derived DC results in the up-regulation of the surface expression of CD83, CD80, CD86, CD54, CD1a and CD40 molecules, the typical DC maturation-associated markers. It also promotes a rapid homotypic aggregation of DC paralleled by the up-regulation of such adhesion molecules as VLA-4, tissue transglutaminase, CD54 and CD11c. The impact of MHC class II cross-linking upon DC was context dependent. The outcome of MHC class II signaling depends on the maturation status of DC. While the cross-linking of MHC class II on immature DC promoted their maturation, the dominant effect upon the DC that were previously matured was the induction of DC apoptosis. Our current observations indicate that, in addition to the previously reported negative impact of MHC class II-mediated signaling on DC function, it also promotes DC maturation, participating in the enhancement of DC stimulatory function. Importantly, MHC class II-induced DC maturation and apoptosis are mediated by different signaling pathways, sensitive to different sets of inhibitors. This opens the possibility of differential regulation of each of these events in immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12202400     DOI: 10.1093/intimm/dxf073

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

1.  Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.

Authors:  Yangbing Zhao; Zhili Zheng; Hung T Khong; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunother       Date:  2006 Jul-Aug       Impact factor: 4.456

2.  DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.

Authors:  Gunnveig Grodeland; Siri Mjaaland; Kenneth H Roux; Agnete Brunsvik Fredriksen; Bjarne Bogen
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

3.  Morphine suppresses MHC-II expression on circulating B lymphocytes via activation of the HPA.

Authors:  Alexandria L Nugent; Richard A Houghtling; Barbara M Bayer
Journal:  J Neuroimmune Pharmacol       Date:  2010-05-04       Impact factor: 4.147

4.  Differential functional effects of biomaterials on dendritic cell maturation.

Authors:  Jaehyung Park; Julia E Babensee
Journal:  Acta Biomater       Date:  2012-06-12       Impact factor: 8.947

Review 5.  Glucocorticoid receptor modulates dendritic cell function in ulcerative colitis.

Authors:  Xinxin Yang; Jingshu Geng; Hongxue Meng
Journal:  Histol Histopathol       Date:  2020-07-24       Impact factor: 2.303

6.  Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients.

Authors:  Andrew Y Chang; Nupur Bhattacharya; Jian Mu; A Francesca Setiadi; Valeria Carcamo-Cavazos; Gerald H Lee; Diana L Simons; Sina Yadegarynia; Kaveh Hemati; Adam Kapelner; Zheng Ming; David N Krag; Erich J Schwartz; Danny Z Chen; Peter P Lee
Journal:  J Transl Med       Date:  2013-10-02       Impact factor: 5.531

7.  Ligation of MHC Class II Induces PKC-Dependent Clathrin-Mediated Endocytosis of MHC Class II.

Authors:  Kento Masaki; Yuhji Hiraki; Hiroka Onishi; Yuka Satoh; Paul A Roche; Satoshi Tanaka; Kazuyuki Furuta
Journal:  Cells       Date:  2020-07-30       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.